|Bid||25.86 x 0|
|Ask||25.87 x 0|
|Day's Range||24.58 - 26.13|
|52 Week Range||11.20 - 29.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Everything's been going so well for Valeant Pharmaceuticals International (VRX). See, Valeant has been on quite a run. Since bottoming at $8.51 in April, Valeant's shares have rallied more than 130% as the beleaguered pharmaceutical company sold off assets, and paid down or extended its debt.
Have Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares just gotten too expensive? Shares are tumbling 10% after a cautious analyst decided it is no longer wise to play it safe, deciding to step away from the sidelines on VRX. The reason? The struggling biotech giant's estimates for the next two years seem too ambitious. Moreover, now after shares have rallied close to 100% from the stock price before the third quarter print, Valeant's valuation simply does not make a "compelling" argument to invest.
In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals' (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.
Shares of Valeant Pharmaceuticals International Inc. dropped 4.3% in premarket trade Thursday, after the drug maker was downgraded at J.P. Morgan, which cited valuation and concerns over patent losses ...
Shares of Valeant Pharmaceuticals (VRX) surged more than 2% higher on Wednesday morning, touching a new 52-week high in the process. As we approach the New Year, it is time to ask: is Valeant officially back?
Shares of Valeant Pharmaceuticals International (VRX) are higher Tuesday, and have easily outperformed this year, to the point that shorts may be throwing in the towel. Today, Cantor Fitzgerald's Louise Chen and her team write that the company has also seen the largest decrease in short interest in her coverage universe as of the end of November. The move comes as Valeant rose from less than $15 in mid-month to nearly $22 today.
Canada's main stock index rose on Tuesday, led by gains in drugmaker Valeant Pharmaceuticals and in the financial services sector. * At 10:18AM ET , the Toronto Stock Exchange's S&P/TSX composite index ...
Every day on PreMarket Prep, hosts Joel Elconin and Dennis Dick highlight over a dozen key morning movers to keep an eye on throughout the day. Below is a trade we thought is particularly hot today. Valeant ...
The trade group representing U.S. drugmakers on Friday said it has a filed a lawsuit to stop California from implementing a law aimed at reining in prescription drug prices. The Pharmaceutical Research and Manufacturers of America (PhRMA), in a statement, said it filed litigation in the U.S. District Court for the Eastern District of California challenging a state law requiring drug manufacturers to give notice and a justification for price increases of certain drugs. The law, Senate Bill 17, was signed by California Governor Jerry Brown in October and is set to take effect Jan. 1, 2019.
Activist investor Bill Ackman and his estranged former collaborator in a 2014 hostile takeover bid for Botox-maker Allergan Inc. will likely face a jury trial next month over claims they engaged in insider ...
The Vetr crowd on Thursday upgraded its rating on Valeant Pharmaceuticals International, Inc. (NYSE: VRX ), from 4 stars (Buy), issued two days ago, to 5 stars. Crowd sentiment at the time of the upgrade ...
Canada's main stock index rose on Thursday, boosted by gains for financial and energy stocks and bounceback rises for discount store chain Dollarama Inc , commerce software company Shopify and Valeant ...
Two years ago, Valeant Pharmaceuticals International Inc. shares plunged off a cliff. Now, some investors are starting to pick them up and dust them off.
Billionaire investor Bill Ackman’s audacious partnership with Valeant Pharmaceuticals International Inc. to make a hostile bid for drug company Allergan Inc. in 2014 brought him a windfall of more than ...
Jim Simons, the founder of one of the world's most successful hedge funds, is splashing out on controversial healthcare stock Valeant Pharmaceuticals (NYSE:VRX). However, this fund guru is displaying a more cautious attitude towards Opko Health (NASDAQ:OPK). Will these moves take his $85 billion fund to new heights?
Valeant Pharmaceuticals sees its Relative Strength Rating move into the elite 90-plus level.
Valeant Pharmaceuticals International Inc., returned to the bond market to start refinancing the more than $4 billion of junk debt that the drugmaker has coming due starting in just over two years. Valeant is weighed down by a $27 billion debt load that it accumulated to fund acquisitions. Valeant has cut its debt burden from around $30 billion at the start of the year through these measures.
Valeant Pharmaceuticals (NYSE:VRX) management boiled down its position to BTIG analyst Tim Chiang, where the discussion gravitated on the standing of the company's three leading segments: Bausch + Lamb/International, Branded Rx, and U.S. Diversified products. The biotech giant is not out of the woods, says Chiang after talking over the company's bigger picture with the VRX team. However, does some growth potential remain for this comeback kid of the Street just yet?